Latest News

• Time has come (again!) to rally for the Promising Pathway Act!        

   PLEASE help support this bill. You can make a huge difference.  I want everyone reading this to email their representatives, and ask 10 of their friends or family to also write.  Spread word on social media!   Follow the link below for a simple way to send the emails!  It is especially important to make sure that Bernie Sanders gets a lot of emails - so if you are from Vermont - get everyone you know to do this!

  
  
• Impact of Reirradiation Utilizing Fractionated Stereotactic Radiotherapy for Recurrent Glioblastoma        

   This doubled survival for recurrent glioblastoma and is easily available. Worth considering.

  
  
• The Cure Starts Now "Once in a Lifetime" Gala and Auction        

   From our good friends at the Cure Starts Now.  This is an amazing event and supports a great cause.   

  
  
• Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress        

   The HUGE news in this report is the FDA set a PDUFA date of April 30, 2024 for their drug tovorafenib  in relapsed or progressive pLGG.  A PDUFA date is the target date for when the FDA will make a decision on approving the drug or not.  Tovorafenib is an investigational, oral, brain-penetrant, highly selective type II RAF kinase inhibitor designed to target a key enzyme in the MAPK signaling pathway, which is also  being investigated in primary brain tumors or brain metastases of solid tumors. Tovorafenib is currently under evaluation in two pivotal clinical trials for pLGG. Tovorafenib is also being evaluated as a combination therapy for adolescent and adult patient populations with recurrent or progressive solid tumors with MAPK pathway aberrations (FIRELIGHT-1).